BMY Reports Mixed Phase III Trial Results, Stock Down

Impact · against what's priced in

BMY faces a net negative catalyst as the inconsistency in admilparant's dose response undermines the probability of a broad FDA approval, outweighing the positive results for RYZ101.

BMY−0.20: No priced-in read yet
In context: While RYZ101 met its primary endpoint for progression-free survival, admilparant's failure to achieve statistical significance at the 120-mg dose creates uncertainty regarding its regulatory path for idiopathic pulmonary fibrosis.
Read from the article alone

BMY Reports Mixed Phase III Trial Results, Stock Down

healthcare
biotech
pharmaceuticals
BMY
cancer research
clinical trials
drug pipeline
pulmonary fibrosis

Search tags

BMY Reports Mixed Phase III Trial Results, Stock Down

What matters in this story

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

BMY Reports Mixed Phase III Trial Results, Stock Down

What matters in this story

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

How each ticker is affected

Track these names every morning.

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway

BMY Reports Mixed Phase III Trial Results, Stock Down

What matters in this story

Next reads from the same story arc

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

BMY Reports Mixed Phase III Trial Results, Stock Down

What matters in this story

Next reads from the same story arc

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

How each ticker is affected

Track these names every morning.

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry

Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway